Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1479587rdf:typepubmed:Citationlld:pubmed
pubmed-article:1479587lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:1479587lifeskim:mentionsumls-concept:C0024188lld:lifeskim
pubmed-article:1479587lifeskim:mentionsumls-concept:C0055819lld:lifeskim
pubmed-article:1479587lifeskim:mentionsumls-concept:C1948041lld:lifeskim
pubmed-article:1479587lifeskim:mentionsumls-concept:C0332256lld:lifeskim
pubmed-article:1479587lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:1479587lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:1479587lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:1479587pubmed:issue26lld:pubmed
pubmed-article:1479587pubmed:dateCreated1993-2-8lld:pubmed
pubmed-article:1479587pubmed:abstractTextCitric acid analogues (+/-)-12a,b and (+/-)-17a,b, where one of the primary carboxylates has been replaced by a sulfoximinoyl and a 3-(3-hydroxy-beta-lactamyl) moiety, respectively, have been synthesized and evaluated as inhibitors of ATP-citrate lyase. The design of these inhibitors was based on methionine sulfoximine and tabtoxinine beta-lactam, potent, tight-binding inhibitors of glutamine synthetase. Both ATP-citrate lyase and glutamine synthetase employ phosphate-carboxylate anhydrides as a method for carboxylate activation during catalysis. Only one diastereomer, (+/-)-12a, displayed weak, reversible inhibition, while the remaining citrate analogues (+/-)-12b and (+/-)-17a,b were inactive against the lyase. No time-dependent inactivation of the enzyme was observed.lld:pubmed
pubmed-article:1479587pubmed:languageenglld:pubmed
pubmed-article:1479587pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1479587pubmed:citationSubsetIMlld:pubmed
pubmed-article:1479587pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1479587pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1479587pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1479587pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1479587pubmed:statusMEDLINElld:pubmed
pubmed-article:1479587pubmed:monthDeclld:pubmed
pubmed-article:1479587pubmed:issn0022-2623lld:pubmed
pubmed-article:1479587pubmed:authorpubmed-author:GrootP HPHlld:pubmed
pubmed-article:1479587pubmed:authorpubmed-author:HughesM JMJlld:pubmed
pubmed-article:1479587pubmed:authorpubmed-author:KruseL ILIlld:pubmed
pubmed-article:1479587pubmed:authorpubmed-author:McNairDDlld:pubmed
pubmed-article:1479587pubmed:authorpubmed-author:WellsT NTNlld:pubmed
pubmed-article:1479587pubmed:authorpubmed-author:SaxtyB ABAlld:pubmed
pubmed-article:1479587pubmed:authorpubmed-author:DolleR ERElld:pubmed
pubmed-article:1479587pubmed:authorpubmed-author:EggelstonDDlld:pubmed
pubmed-article:1479587pubmed:issnTypePrintlld:pubmed
pubmed-article:1479587pubmed:day25lld:pubmed
pubmed-article:1479587pubmed:volume35lld:pubmed
pubmed-article:1479587pubmed:ownerNLMlld:pubmed
pubmed-article:1479587pubmed:authorsCompleteYlld:pubmed
pubmed-article:1479587pubmed:pagination4875-84lld:pubmed
pubmed-article:1479587pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:1479587pubmed:meshHeadingpubmed-meshheading:1479587-...lld:pubmed
pubmed-article:1479587pubmed:meshHeadingpubmed-meshheading:1479587-...lld:pubmed
pubmed-article:1479587pubmed:meshHeadingpubmed-meshheading:1479587-...lld:pubmed
pubmed-article:1479587pubmed:meshHeadingpubmed-meshheading:1479587-...lld:pubmed
pubmed-article:1479587pubmed:meshHeadingpubmed-meshheading:1479587-...lld:pubmed
pubmed-article:1479587pubmed:meshHeadingpubmed-meshheading:1479587-...lld:pubmed
pubmed-article:1479587pubmed:meshHeadingpubmed-meshheading:1479587-...lld:pubmed
pubmed-article:1479587pubmed:meshHeadingpubmed-meshheading:1479587-...lld:pubmed
pubmed-article:1479587pubmed:meshHeadingpubmed-meshheading:1479587-...lld:pubmed
pubmed-article:1479587pubmed:year1992lld:pubmed
pubmed-article:1479587pubmed:articleTitleATP-citrate lyase as a target for hypolipidemic intervention. Sulfoximine and 3-hydroxy-beta-lactam containing analogues of citric acid as potential tight-binding inhibitors.lld:pubmed
pubmed-article:1479587pubmed:affiliationDepartment of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals Ltd., The Frythe, Welwyn, Hertfordshire, U.K.lld:pubmed
pubmed-article:1479587pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:1479587lld:chembl